U.S. Supreme Court
Jun. 19, 2024
US Supreme Court rejects challenge to mifepristone
The Supreme Court unanimously decided that the Alliance for Hippocratic Medicine and other parties did not have standing to challenge the FDA’s approval of the abortion-inducing drug mifepristone in 2000, nor the FDA’s relaxations of some restrictions on the drug’s use.
Philip M. Howe
Howe is a member of the California and Massachusetts State Bars, having last practiced in California in 2019.
In a unanimous decision on June 13, 2024, the Supreme Court ruled that the Alliance for Hippocratic Medicine and others lacked standing to challenge the F.D.A.’s 2000 approval of this abortion-inducing drug and the F.D.A.’s 2016, 2019 and 2021 relaxing of some of their restrictions for the drug’s use. Justice Kavanaugh wrote the opinion for the Court.
Food and Drug Administration et. al. v. Alliance for H...
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In